Treating ITP patients ?

advance SC
immune thrombocytopenia study

The ADVANCE SC clinical study is looking at an investigational study drug in ITP patients.

ABOUT THE SPONSOR OF THE STUDY.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into novel antibody-based medicines. argenx developed and is commercializing a neonatal Fc receptor (FcRn) blocker in the U.S., Japan and the EU.
The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

argenx

ABOUT THE STUDY.

The Advance SC study is a Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of the Investigational Study Drug Efgartigimod PH20 SC in Adult Patients with Primary Immune Thrombocytopenia.

Efgartigimod is an investigational study drug that is currently not approved for use in primary immune thrombocytopenia (ITP) by any regulatory agency, as safety and effectiveness have not been established.

Enrolled patients will be asked to go to weekly study site visits approximately 28 times. The study will last for up to 35 weeks. This will include up to 2 weeks of screening, 24-week treatment period, end of treatment visit (1 week after visit 24), and 8 weeks of follow up.

If patients complete the 24-week treatment period and all criteria are met, they may have an opportunity to join the open label extension study where everyone participating will receive the investigational study drug, efgartigimod.

For more details please consult
https://www.clinicaltrials.gov/ct2/show/NCT04687072

advance SC
immune thrombocytopenia study

ABOUT THE MOLECULE.

Efgartigimod is a human IgG1 investigational antibody fragment to target the neonatal Fc receptor (FcRn).

Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists.

If you would like to receive more information or have questions about efgartigimod clinical development, please contact medinfo@argenx.com

Considering to refer an ITP patient to an investigational site ?

The ADVANCE SC participating sites are:

NORWAY

SARPSBORG OSLO - Dr GHANIMA

ITALY

REGGIO CALABRIA - Dr OLIVA
MILANO - Dr ARTONI
NOVARA - Dr PATRIARCA
REGGIO EMILIA - Dr GAMBERI
TERNI - Dr BARCELLINI
TERNI - Dr LIBERATI
VARESE - Dr CARAMAZZA
NAPOLI - Dr FERRARA
CONA - Dr CUNEO
NAPOLI - Dr PANE
MELDOLA - Dr LUCCHESI
ROMA - Dr ROSSI

SPAIN

VALENCIA - Dr JARQUE RAMOS
BARCELONA - Dr SANCHEZ GONZALES
BARCELONA - Dr VALCARCEL FERREIRAS
BARCELONA - Dr NOVELLI CANALES
ALAVA - Dr BUENDIA UREÑA
MADRID - Dr BOLANOS CALDERON

UK

COVENTRY - Dr BAILIF
LONDON - Dr Mc DONALD
LONDON - Dr COOPER
TRURO - Dr FORBES

Please reach out to a site nearby your location if you think you have a potential ITP patient susceptible for participation.

Thank you.